ArticleJournal of clinical pathology2009
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.
Article in Journal of clinical pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review.Molecular biology reports · 2021Pooled it
- EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.Journal of hematology & oncology · 2012Pooled it
- Trial
- Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Trial
- A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Epidermal Growth Factor Receptor (EGFR) Amplification May Lead to Invalid Cobas EGFR Mutation Test v2 Results.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.PloS one · 2024Article
- Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.JTO clinical and research reports · 2023Article
- Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.Cancers · 2022Review
- HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.Thoracic cancer · 2021Article
- Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.Translational lung cancer research · 2020Article
- H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.The Journal of pathology · 2020Article
- Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.Japanese journal of clinical oncology · 2020Article
- Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.PloS one · 2019Article
- Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients withTuberculosis and respiratory diseases · 2019Article
- EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.Journal of cancer research and clinical oncology · 2016Article
- Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2015Article
- ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer.The journal of pathology. Clinical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a need for predictive biomarkers that identify non-small-cell lung cancer (NSCLC) patients most likely to respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. There are numerous potential candidates, although none has been proven in prospective clinical trials. The EGFR gene copy number evaluated by fluorescence in situ hybridisation (FISH) has been highlighted as one of the most effective markers for sensitivity to EGFR TKIs in large phase III, randomised placebo-controlled trials and has been used in clinical settings to assist physicians in defining the therapeutic regimen. The EGFR FISH assay has technical challenges and it is critical that detailed guidelines are provided to help clinical laboratories in performing and interpreting the test. Excellent assay reproducibility and portability rates among laboratories are crucial to guarantee that accurate clinical decisions can be made for patients with NSCLC. This article discusses the consensus outcomes of a global workshop convened to discuss key technical issues and standardise reading strategies for the EGFR FISH assay of NSCLC tumour tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.